About Us | Contact Us | Site Map | ©2005-2007 CoDa Therapeutics, Inc. All rights reserved Terms of Use
ABOUT CODA THERAPEUTICS
CoDa Therapeutics, Inc. is a San Diego-based pharmaceutical company focused on the development and commercialization of wound care and tissue repair therapeutics based on gap junction modulation. A single topical application of CoDa’s patented, anti-connexin compounds downregulate the proteins that form gap junctions leading to a temporary reduction in cell to cell communication. The Company's proprietary therapeutic compounds have consistently demonstrated, in both ocular and skin indications, an enhanced rate of wound healing combined with a reduction of lesion spread (cell death), inflammation, swelling and scarring.
NEWS
| 02/21/07 | CoDa Therapeutics Secures $10.0 Million in Additional Series A Financing |
| 10/10/06 | CoDa Therapeutics Announces Series A Financing |
| PIPELINE |
| CoDa’s initial target markets are patients with eye damage caused by surgery or mechanical injury, and acute surgical wounds. |
| CoDa anticipates entering the clinic with initial trials in eye and skin scheduled for 2007 and 2008. |